-mutant advanced non-small-cell lung cancer, discussing the biological rationale underlying the development of a forefront combination of TKI and/or new antibody-drug conjugates. We also suggest a treatment algorithm that could be followed considering the latest published data.
No takes yet. Share an insight, caveat, or question.
Pecci et al. (2022) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: